DE69432790D1 - Auf papillomaviren basierende pharmazeutische präparate - Google Patents

Auf papillomaviren basierende pharmazeutische präparate

Info

Publication number
DE69432790D1
DE69432790D1 DE69432790T DE69432790T DE69432790D1 DE 69432790 D1 DE69432790 D1 DE 69432790D1 DE 69432790 T DE69432790 T DE 69432790T DE 69432790 T DE69432790 T DE 69432790T DE 69432790 D1 DE69432790 D1 DE 69432790D1
Authority
DE
Germany
Prior art keywords
fragment
formulation
protein
papillomavirus
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69432790T
Other languages
English (en)
Other versions
DE69432790T2 (de
Inventor
Severia Campo
William Fleming Hoggan Jarrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Campaign Technology Ltd
Original Assignee
Cancer Research Campaign Technology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Research Campaign Technology Ltd filed Critical Cancer Research Campaign Technology Ltd
Publication of DE69432790D1 publication Critical patent/DE69432790D1/de
Application granted granted Critical
Publication of DE69432790T2 publication Critical patent/DE69432790T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DE69432790T 1993-03-31 1994-03-31 Auf papillomaviren basierende pharmazeutische präparate Expired - Fee Related DE69432790T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB939306731A GB9306731D0 (en) 1993-03-31 1993-03-31 Vaccines
GB9306731 1993-03-31
PCT/GB1994/000683 WO1994023037A1 (en) 1993-03-31 1994-03-31 Pharmaceuticals based on papillomaviruses

Publications (2)

Publication Number Publication Date
DE69432790D1 true DE69432790D1 (de) 2003-07-10
DE69432790T2 DE69432790T2 (de) 2004-04-22

Family

ID=10733089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69432790T Expired - Fee Related DE69432790T2 (de) 1993-03-31 1994-03-31 Auf papillomaviren basierende pharmazeutische präparate

Country Status (12)

Country Link
US (1) US6020309A (de)
EP (1) EP0692028B1 (de)
JP (1) JPH08508728A (de)
AT (1) ATE242265T1 (de)
AU (1) AU6381794A (de)
CA (1) CA2158554A1 (de)
DE (1) DE69432790T2 (de)
DK (1) DK0692028T3 (de)
ES (1) ES2199960T3 (de)
GB (1) GB9306731D0 (de)
PT (1) PT692028E (de)
WO (1) WO1994023037A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM358894A0 (en) * 1994-01-31 1994-02-24 Csl Limited Modified papilloma virus l2 protein and vlps formed therefrom
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
AU781653B2 (en) * 1996-07-30 2005-06-02 Transgene S.A. Pharmaceutical composition for treating papollomavirus tumour and infection
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
US8128922B2 (en) 1999-10-20 2012-03-06 Johns Hopkins University Superior molecular vaccine linking the translocation domain of a bacterial toxin to an antigen
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
EP1305039B1 (de) * 2000-07-06 2008-12-31 Georgetown University Stabile (fixierte) formen von viralen l1 capsidproteinen, deren fusionsproteinen, und deren verwendungen
AU2001290520A1 (en) * 2000-08-01 2002-02-13 The Johns Hokpins University Intercellular transport protein linked to an antigen as a molecular vaccine
US7342002B2 (en) * 2000-08-03 2008-03-11 The Johns Hopkins University Molecular vaccine linking an endoplasmic chaperone polypeptide to an antigen
EP1644048B1 (de) * 2003-05-05 2015-04-29 Johns Hopkins University Anti-krebs-dna-vakzine mit einer für plasmide kodierenden signalsequenz, mutiertes onkoprotein-antigen und hitzeschockprotein
AU2005322960A1 (en) * 2005-01-06 2006-07-13 The Johns Hopkins University RNA interference that blocks expression of pro-apoptotic proteins potentiates immunity induced by DNA and transfected dendritic cell vaccines
EP1846026A4 (de) * 2005-01-26 2008-07-02 Univ Johns Hopkins Antikrebs-dna-impfstoff mit plasmiden zur kodierung eines mutierten onkoprotein-antigens und von calreticulin
AU2006210792B2 (en) * 2005-02-01 2012-07-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus L2 N-terminal peptides for the induction of broadly cross-neutralizing antibodies
US20100330105A1 (en) * 2006-08-22 2010-12-30 John Hopkins University Anticancer Combination Therapies
US9085638B2 (en) 2007-03-07 2015-07-21 The Johns Hopkins University DNA vaccine enhancement with MHC class II activators
US20080260765A1 (en) * 2007-03-15 2008-10-23 Johns Hopkins University HPV DNA Vaccines and Methods of Use Thereof
US20090285861A1 (en) * 2008-04-17 2009-11-19 Tzyy-Choou Wu Tumor cell-based cancer immunotherapeutic compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0133123A1 (de) * 1983-07-25 1985-02-13 Mgi Pharma, Inc. Papillomavirus-Immunogene
US5180806A (en) * 1988-05-16 1993-01-19 The Scripps Research Institute Polypeptides and compositions of human papillomavirus latent proteins, diagnostic systems and methods
FR2641081A1 (de) * 1988-12-23 1990-06-29 Medgenix Group
AU8762991A (en) * 1990-09-26 1992-04-15 Bristol-Myers Squibb Company Human papilloma viral protein expression for use in vaccine compositions
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
ATE332973T1 (de) * 1991-07-19 2006-08-15 Univ Queensland Polynukleotidabschnitt des hpv16-genoms
GB9207701D0 (en) * 1992-04-08 1992-05-27 Cancer Res Campaign Tech Papillomavirus e7 protein

Also Published As

Publication number Publication date
ES2199960T3 (es) 2004-03-01
DK0692028T3 (da) 2003-09-29
JPH08508728A (ja) 1996-09-17
GB9306731D0 (en) 1993-05-26
AU6381794A (en) 1994-10-24
US6020309A (en) 2000-02-01
EP0692028B1 (de) 2003-06-04
WO1994023037A1 (en) 1994-10-13
ATE242265T1 (de) 2003-06-15
DE69432790T2 (de) 2004-04-22
CA2158554A1 (en) 1994-10-13
PT692028E (pt) 2003-10-31
EP0692028A1 (de) 1996-01-17

Similar Documents

Publication Publication Date Title
DE69432790D1 (de) Auf papillomaviren basierende pharmazeutische präparate
NO982497L (no) Vaksine-sammensetninger for inntak gjennom nesen
EP0784471A4 (de) Facettenreiches verfahren zur unterdrückung der vermehrung latenter viren in menschen und tieren
IN153212B (de)
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
NO963053D0 (no) Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav
DK0695171T3 (da) Lyosfærer indeholdende gonadotropin
ATE260658T1 (de) Pharmazeutische zubereitungen zur verminderung von atmungsdepressionen
FI970788A0 (fi) Kasveilla käytettäviksi tarkoitettuja suihkutettavissa olevia, kalvon muodostavia järjestelmiä vaikuttavien aineiden antamiseksi
DE69429871D1 (de) Pharmazeutische emulsion
AU2147992A (en) Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
ATE171066T1 (de) Pharmazeutische zubereitungen mit einem wirkstoff, der modifizierte amidingruppen enthält
DE69319432D1 (de) Peptide aus Derivaten der 4-Amino-2.2.-Difluoro-3-Oxo-1.6-Hexandisäure als Wirkstoffe gegen Entzündungen
ES2108422T3 (es) Combinaciones sinergicas de productos antisolares y composiciones cosmeticas y dermatologicas que las contienen.
NO972623L (no) Farmasöytisk blanding omfattende lamotrigin
ES2122015T3 (es) Uso de urodilatina en enfermedades pulmonares y bronquiales.
DE69302677T2 (de) Liposomale piroxycam formulierung
FI934680A0 (fi) Arylmorfolin, framstaellning och anvaending
WO1999053950A3 (en) Live vaccines and methods of treatment therewith
SE9303853D0 (sv) The use of an ester of inositoltrisphosphate for the preparing of medicaments
EP0529019A4 (en) Nematode vaccine
MX9302272A (es) Retinoides solubles en agua.
KR920008035A (ko) 타이로신 유도체 및 그 제조방법
SE9401596D0 (sv) New compounds
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee